Intervention Review

Intravenous immunoglobulin for myasthenia gravis

  1. Philippe Gajdos1,*,
  2. Sylvie Chevret2,
  3. Klaus V Toyka3

Editorial Group: Cochrane Neuromuscular Group

Published Online: 12 DEC 2012

Assessed as up-to-date: 11 OCT 2011

DOI: 10.1002/14651858.CD002277.pub4

How to Cite

Gajdos P, Chevret S, Toyka KV. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No.: CD002277. DOI: 10.1002/14651858.CD002277.pub4.

Author Information

  1. 1

    Hopital Raymond Poincaré (APHP), Service de Réanimation, 92380 Garches, Ile de France, France

  2. 2

    Hôpital Saint Louis, Departement de Biostatistique et Informatique Médicale, 75475 Paris, France

  3. 3

    University of Würzburg, Neurology, Würzburg, Bavaria, Germany

*Philippe Gajdos, Service de Réanimation, Hopital Raymond Poincaré (APHP), 104, Boulevard Raymond Poincaré, 92380 Garches, Ile de France, France.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 12 DEC 2012


Options for accessing this content:

  • If you are a society or association member and require assistance with obtaining online access instructions please contact our Journal Customer Services team.
  • Login via other institutional login options
  • You can purchase online access to this Article for a 24-hour period (price varies by title)
    • If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
    • New Users: Please register, then proceed to purchase the article.

Login via OpenAthens


Search for your institution's name below to login via Shibboleth.

Please register to:

  • Save publications, articles and searches
  • Get email alerts
  • Get all the benefits mentioned below!

Register now >

Patient Access

Patients and/or caregivers may access this content for use in relation to their own personal healthcare or that of a family member only. Terms and conditions will apply.